Proton Pump Inhibitor vs Vonoprazan Triple Therapy for H. pylori Eradication, With or Without Zinc

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 3 trial compares two regimens for treating Helicobacter pylori infection: a vonoprazan-based triple therapy and a proton pump inhibitor-based triple therapy, each combined with amoxicillin and clarithromycin, for 14 days. It also evaluates whether adding zinc to the regimen provides additional benefit. Participants are adults with confirmed H. pylori infection who have not received prior treatment for this infection. The study monitors safety and eradication success, with eradication confirmed at least four weeks after completing therapy. Location is at the National Liver Institute in Shibin El Kawm, Egypt, led by Tanta University.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18.
* Both males and females.
* Patients who are positive for H.pylori infection by non-invasive Stool Antigen Test (SAT).

Exclusion Criteria:

* Prior H. pylori treatment: Previous treatment for H. pylori infection.
* Allergies: Known allergies to study medications or components.
* Patients cannot finish treatment course.
* Pregnant and Lactating Women.
* Patients with Kidney disease and eGFR \< 30ml/min.
* Patients with Liver disease with Child-Pugh B or C.

Where it's running

• National Liver Institute
  Shibīn al Kawm, Egypt Recruiting

Study contacts

• Study coordinator: Eman A Mahmoud, Prof.
• Email: eabdelsameea@liver-eg.eg
• Phone: +201002415022

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dual vonoprazan and amoxicillin therapy for Helicobacter pylori infection in Uruguay

  This trial tests whether a two-drug regimen (vonoprazan and amoxicillin for 14 days) can be as effective as the standard four-drug regimen for eradicating H. pylori in adults in Uruguay, with fewer side effects.

  Recruiting at 3 sites Phase 4 Hospital de Clínicas Dr. Manuel Quintela · Maldonado, Departamento de Maldonado and 3 other locations · NCT07924098

• Dual-drug therapy with linlarase glutarate and amoxicillin vs bismuth quadruple therapy for first-line Helicobacter pylori eradication

  This trial tests whether a dual-drug regimen of linlarase glutarate capsules plus amoxicillin can match the effectiveness of a standard bismuth-containing quadruple therapy for first-line Helicobacter pylori eradication.

  Recruiting at 24 sites Phase 4 Xijing Hospital of Digestive Diseases · Zhengzhou, Henan and 23 other locations · NCT07897994

• Feasibility of FFPE qPCR to Detect H. pylori and Clarithromycin Resistance

  This study tests whether tissue samples already collected during gastroscopy can be used with qPCR to find Helicobacter pylori and its clarithromycin resistance.

  Recruiting Clinique Bizet · Paris · NCT07821294

• Adding bismuth to vonoprazan‑amoxicillin therapy for H. pylori

  This study will test whether adding bismuth to a 14-day vonoprazan‑amoxicillin regimen improves H. pylori cure rates in adults who have never had eradication therapy.

  Recruiting Phase 3 National Taiwan University Hospital · Taipei · NCT07576959

• Endoscopic screening for H. pylori, intestinal metaplasia, and Barrett's mucosa during screening colonoscopy

  This project will try adding a gastroscopy with biopsies to routine screening colonoscopy to see how often H. pylori and early stomach changes appear in adults without upper GI symptoms.

  Recruiting Sigmund Freud PrivatUniversitat · Vienna · NCT07346521

• Registry for managing Helicobacter pylori infection in Shandong Province

  This registry will collect real-world information on H. pylori treatments given to adults in Shandong Province to see which approaches work best and are safest.

  Recruiting Qilu Hospital of Shandong University · Jinan, Shandong and 1 other locations · NCT07335406

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.